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ABSTRACT
OBJECTIVES The aim of this study was to determine whether short-term treatment with perhexiline improves cardiac
energetics, left ventricular function, and symptoms of heart failure by altering cardiac substrate utilization.
BACKGROUND Perhexiline improves exercise capacity and left ventricular ejection fraction (LVEF) in patients with
heart failure (HF). 31P cardiac magnetic resonance spectroscopy can be used to quantify the myocardial phosphocreatine/
adenosine triphosphate ratio. Because improvement of HF syndrome can improve cardiac energetics secondarily, we
investigated the effects of short-term perhexiline therapy.
METHODS Patients with systolic HF of nonischemic etiology (n ¼ 50, 62 " 1.8 years of age, New York Heart Association
functional class II to IV, LVEF: 27.0 " 1.44%) were randomized to receive perhexiline 200 mg or placebo for 1 month in a
double-blind fashion. Clinical assessment, echocardiography, and 31P cardiac magnetic resonance spectroscopy were
performed at baseline and after 1 month. A substudy of 22 patients also underwent cross-heart blood sampling at
completion of the study to quantify metabolite utilization.
RESULTS Perhexiline therapy was associated with a 30% increase in the phosphocreatine/adenosine triphosphate ratio
(from 1.16 " 0.39 to 1.51 " 0.51; p < 0.001) versus a 3% decrease with placebo (from 1.36 " 0.31 to 1.34 " 0.31;
p ¼ 0.37). Perhexiline therapy also led to an improvement in New York Heart Association functional class compared with
placebo (p ¼ 0.036). Short-term perhexiline therapy did not change LVEF. Cross-heart measures of cardiac substrate
uptake and respiratory exchange ratio (which reﬂects the ratio of substrates used) did not differ between patients who
received perhexiline versus placebo.
CONCLUSIONS Perhexiline improves cardiac energetics and symptom status with no evidence of altered cardiac
substrate utilization. No change in LVEF is seen at this early stage. (Metabolic Manipulation in Chronic Heart Failure;
NCT00841139) (J Am Coll Cardiol HF 2015;-:-–-) © 2015 by the American College of Cardiology Foundation.
D espite recent advances in treatment, heartfailure (HF) has devastating effects onsurvival (1) and quality of life (2). Pharmacological therapy consists of diuretics andneurohormonal modulating agents. It is well estab-lished that energy deﬁciency contributes to the
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syndrome of HF (3), and this has been pro-
posed as a therapeutic target.
In previous phase 2 studies, beneﬁcial ef-
fects of perhexiline have been observed in
refractory angina (4), HF (5), and hypertro-
phic cardiomyopathy (6). This is subject to
variable metabolism by P4502D6, of which
there are several polymorphic variants.
Sustained high plasma levels may lead to
hepatotoxicity and neurotoxicity due to
phospholipid accumulation in these tissues.
It has been shown that toxicity is avoided by
plasma monitoring with dose titration (7).
The therapeutic effects of perhexiline have
been believed to relate to altered cardiac
substrate utilization. Perhexiline has been
shown to inhibit carnitine palmitoyltransfer-
ase 1 and, to a lesser extent, carnitine palmi-
toyltransferase 2 (8). These mitochondrial
enzymes facilitate entry of medium- and
long-chain fatty acids into mitochondria to
undergo beta-oxidation and subsequently
produce adenosine triphosphate (ATP). This inhibi-
tion of fatty acid metabolism may be expected to
lead to a reciprocal increase in carbohydrate activa-
tion (via allosteric activation of the enzyme pyruvate
dehydrogenase) and thus an improvement in myo-
cardial efﬁciency and phosphocreatine (PCr)/ATP
ratio.
31P cardiac magnetic resonance spectroscopy (31P
MRS) allows noninvasive quantiﬁcation of the
PCr/ATP ratio, which is an accepted measure of car-
diac energetic status. It has been shown that the
PCr/ATP ratio is reduced in the failing human heart
(9,10). Therefore, we sought to determine whether
the therapeutic beneﬁt of perhexiline in HF is related
to an improved cardiac PCr/ATP ratio and whether
this is a consequence of altered cardiac substrate
utilization. Effective therapy for HF that does not act
in the ﬁrst instance by direct effects on cardiac
metabolism may nevertheless in the longer term
result in improvements in the cardiac PCr/ATP ratio
via an improvement in HF syndrome, leading in turn
to molecular reverse remodeling of maladaptive
changes in genes involved in cardiac metabolism and
calcium handling and thereby potentially to a vir-
tuous cycle of improved cardiac function (11–13). In
this study, we hypothesized that perhexiline therapy
would improve the cardiac PCr/ATP ratio in patients
with HF by altering cardiac substrate utilization. To
assess whether these changes occur early and are by
inference directly responsible for the subsequent
improvement in cardiac function, we used a short-
term (1-month) regimen of perhexiline that typically
resulted in plasma perhexiline levels in the low
therapeutic range for approximately 2 weeks.
METHODS
STUDY DESIGN. This randomized, double-blind, pla-
cebo-controlled, parallel-group study explored the
effects of perhexiline over 1 month (32 [29 to 35] days)
in patients with symptomatic, nonischemic cardio-
myopathy. All participants provided written in-
formed consent, and research was performed in
accordance with the Declaration of Helsinki. The pre-
deﬁned primary endpoint was an increase in the
cardiac PCr/ATP ratio with perhexiline therapy com-
pared with placebo. The secondary endpoints were
improvement in New York Heart Association (NYHA)
functional class, quality of life (Minnesota Living
With Heart Failure Questionnaire [MLWHFQ]), and
left ventricular ejection fraction (LVEF). In a sub-
group of 22 patients, cross-heart respiratory exchange
ratio (RER) was measured to assess cardiac substrate
utilization. The study protocol and methodology
have been previously reported (14). The study was
approved by the South Birmingham Research
Ethics Committee (06/Q2707/7) and the Medicines
and Healthcare Products Regulatory Agency (21761/
0003/001) and was registered with ClinicalTrials.gov
(NCT00841139).
PATIENT SELECTION. Patients (n ¼ 50) were consec-
utively recruited from the Advanced HF Programme at
the University Hospitals Birmingham NHS Foundation
Trust (Birmingham, England) and the University
Hospitals of Wales NHS Trust (Cardiff, Wales) between
February 2008 and June 2011. All patients were
receiving maximal tolerated doses of evidence-based
HF therapy (angiotensin-converting enzyme in-
hibitors, beta-blockers, and mineralocorticoid recep-
tor antagonists). Inclusion criteria were nonischemic
dilated cardiomyopathy, symptoms of HF despite
optimal tolerated medical therapy, and LVEF <40%
on echocardiography. Patients with a history of coro-
nary heart disease and with cardiac rhythms other
than sinus were not included. Exclusion criteria were
a history of liver disease or liver function test mea-
surements greater than twice the upper limit of
normal; concomitant use of amiodarone, quinidine,
haloperidol, or selective serotonin reuptake inhibitors
that inhibit the CYP2D6 enzyme; pre-existing evi-
dence of peripheral neuropathy; women of child-
bearing potential; and contraindications to MRS.
Patients underwent a clinical assessment, in-
cluding assessment of NYHA functional class and
quality of life (MLWHFQ). They also under-
went venous blood sampling, 31P MRS, and
ABBR EV I A T I ON S
AND ACRONYMS
ATP = adenosine triphosphate
CRLB = Cramer-Rao lower
bound
HF = heart failure
LVEF = left ventricular ejection
fraction
MLWHFQ = Minnesota Living
With Heart Failure
Questionnaire
NEFA = nonesteriﬁed fatty
acids
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
NYHA = New York Heart
Association
31P MRS = 31P cardiac magnetic
resonance spectroscopy
PCr = phosphocreatine
RER = respiratory exchange
ratio
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echocardiography before and after the intervention. A
subgroup of patients underwent invasive testing with
cross-heart sampling at the end of the study to
investigate on-treatment differences in cardiac sub-
strate utilization between the perhexiline and pla-
cebo groups. These patients satisﬁed the same
inclusion criteria but gave consent for the additional
invasive component of the study.
INTERVENTION. After baseline studies were per-
formed, patients were randomized in a double-blind
fashion with a block size of 5 to receive either per-
hexiline 200 mg once daily (n ¼ 25) or placebo
(n ¼ 25). Serum perhexiline levels were obtained at 1
and 4 weeks after initiation of the drug. Dose ad-
justments were advised by an unblinded physician
according to serum level to achieve a therapeutic
level (therapeutic range: 0.15 to 0.6 mg/l) and to avoid
drug toxicity according to a protocol devised by Hor-
owitz et al. (7). Identical dosage adjustments were
made by the unblinded observer for patients receiving
placebo to ensure that blinding of the investigators
was maintained as described previously (14).
VENOUS BLOOD. All venous samples obtained before
and after treatment were analyzed for levels of
glucose, glycerol, lactate, nonesteriﬁed fatty acids
(NEFA), triglycerides, pyruvate, insulin, and N-
terminal pro–B-type natriuretic peptide (NT-proBNP).
A Kone 20i selective chemistry analyzer (Thermo-
Fisher Scientiﬁc UK Ltd., Loughborough, England)
was used for measurement of glucose, glycerol,
lactate, NEFA, lactate, and triglyceride levels using a
colorimetric method. Pyruvate levels were deter-
mined by enzymatic assay (kit ref ab65342, Abcam,
Cambridge, England). Insulin levels were quantiﬁed
using an enzyme-linked immunosorbent assay kit (kit
ref EZHI-14K, Merck Millipore, Watford, England).
Plasma concentrations of NT-proBNP were deter-
mined using an immunoluminometric assay (15). Pa-
tients who had plasma triglyceride levels >2.5 mmol/l
were assumed not to have fasted, and their samples
were excluded from analysis of insulin and
metabolites.
Myocard ia l energet ic s . Cardiac high-energy phos-
phate metabolism was measured using 31P MRS on a
3-T Philips Achieva whole-body magnet (Philips
Healthcare, Reigate, Surrey, England) using a linearly
polarized transmit-and-receive P-31 coil with a diam-
eter of 14 cm. Localization was achieved by image-
selected in vivo spectroscopy volume selection. The
participants were placed in a supine position with
the coil directly over the precordium. The coil was
secured in place by straps around the upper body and
coil. The participants were then positioned inside the
magnet with the center of the coil at the isocenter of
the magnet. Survey images were obtained to check the
position of the coil. The subjects and/or the coil were
repositioned if required to ensure that the distance
between the coil and septum and apex of the heart was
minimized and signal strength maximized. Localized
iterative ﬁrst-order shimming was performed over the
entire heart using the unsuppressed water signal ac-
quired with the body coil as reference. The shimming
process involves an automated hydrogen-1 spectral
acquisition to test the quality of the shim, which is
expressed as full width at half maximum. This was
repeated until a full width at half maximum of <40 Hz
was achieved. A short-axis cine scan was performed to
calculate the trigger delay for electrocardiographic
triggering and to check the quality of shimming and
F0 determination. The trigger delay was calculated
such that the spectra were acquired in the diastolic
period, when the heart is as still as possible. The 3-
dimensional in vivo spectroscopy voxel of acquisi-
tion was planned to include most of the septum and
apex of the heart within the shimmed area. Care was
taken to minimize blood contamination from the right
ventricle, liver, and skeletal muscle. The voxel size
was kept constant at 89.54ml (44# 55# 37mm3). After
this, the 31P spectrum was acquired with a repetition
time of 10,000 ms, 136 averages, and 512 samples. A
repetition time of 10,000 ms was found to be optimal
for adequate reduction of saturation effects without
greatly increasing the scan time. The average scan
time was 23 min. The spectra were analyzed and
quantiﬁed using the Java-based Magnetic Resonance
User Interface (jMRUI) software. Post-processing was
performed with 15-Hz Gaussian line broadening
and Fourier transformation. Phase correction was
performed with the PCr peak as the reference
peak. Quantiﬁcation was performed with AMARES
(Advanced Method for Accurate, Robust and Efﬁcient
Spectral ﬁtting), a time domain ﬁtting program, which
involves selecting peaks and deﬁning their line width.
The concentrations of PCr, ATP (g, a, and b), and
2,3-diphosphoglycerate were calculated as the area
under the peaks. The PCr/ATP ratio was determined
after correcting the gATP peak for blood contamina-
tion as described previously on the basis of the quan-
tity of 2,3-diphosphoglycerate in the derived spectrum
(16). A single, blinded operator experienced in the
technique performed the analysis.
Cramer-Rao lower bounds (CRLBs) were calculated
to assess the quality of the spectral ﬁt. The CRLBs are
the lowest possible SDs of all unbiased model
parameter estimates obtained from the data and are
widely used as a measure of attainable precision of
parameter estimates (17).
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Symptom status . NYHA functional class was deter-
mined in all patients by the same blinded cardiologist
asking a standard set of questions (18). Quality of life
was assessed with the standard 21-question MLWHQ.
All patients completed questionnaires alone and
without assistance.
Echocard iography . Standard transthoracic echo-
cardiography (Vivid 7, GE Vingmed Ultrasound,
Horten, Norway) was performed by an experienced
echocardiographer using second harmonic imaging
and an M3S multifrequency transducer. All parame-
ters were measured in triplicate and averaged ac-
cording to the recommendations of the American
Society of Echocardiography (19). Analysis was per-
formed ofﬂine by a single blind observer using an
EchoPAC workstation (GE Vingmed Ultrasound).
Grayscale images for 2-dimensional left ventricular
strain were acquired from the apical 4-, 2-, and 3-
chamber views and parasternal short-axis views at
basal, papillary, and apical ventricular levels at end
expiration at frame rates >70 Hz for speckle tracking
echocardiography. Analysis was performed ofﬂine
using commercially available software (GE Vingmed
Ultrasound, Horten, Norway). Peak systolic velocities,
strain, strain rate, rotation, and twist were measured
for each myocardial segment in triplicate and aver-
aged for global estimates.
Cross-hear t sampl ing . A coronary sinus thermodi-
lution catheter was inserted via a 7-F sheath placed in
either the right internal jugular vein or right femoral
vein under local anesthesia. The catheter was guided
into place using ﬂuoroscopy and small injections of
FIGURE 1 CONSORT Trial Flow Diagram
A total of 1,637 patients were screened for inclusion, 278 met the inclusion criteria, and 50 were randomized. One patient was lost to follow-up.
Twenty-two patients in each group underwent cardiac 31P MRS. CONSORT ¼ Consolidated Standards of Reporting Trials; MRS ¼ magnetic
resonance spectroscopy; SNR ¼ signal-to-noise ratio.
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radio-opaque contrast when required to conﬁrm the
position of the catheter. This catheter was used to
take venous blood samples from the coronary sinus as
well as to measure ﬂow by thermodilution. Arterial
samples were taken simultaneously from an arterial
sheath. No heparin was used until these samples had
been taken. Samples were spun immediately in
ethylenediaminetetraacetic acid, and plasma was
frozen in liquid nitrogen and stored at $80%C. These
samples were analyzed in a single batch at the end of
the study for glucose, lactate, NEFA, and pyruvate.
Blood samples for oxygen were taken in blood gas
syringes, and measurement of oxygen was performed
using a Bayer Rapidlab 800 series blood gas analyzer
(Bayer Healthcare LLC, East Walpole, Massachusetts).
Measurement of carbon dioxide was performed
off site with isotope-ratio mass spectrometry using
a Thermo Finnigan Delta XP isotope ratio mass
spectrometer (Thermo Fisher Scientiﬁc UK, Lough-
borough, England).
Stat i s t i ca l ana lys i s . Variables are expressed as
mean " SD when normally distributed or median and
interquartile range when not normally distributed.
Continuous variables were compared between base-
line data for perhexiline and placebo using unpaired
Student t test (2-tailed) if variables were normally
distributed and the Mann-Whitney U test if the data
were non-normally distributed. The Kolmogorov-
Smirnov test and normality plots were used to
assess normality of continuous variables. Categorical
variables were compared with the Pearson chi-
square test. NYHA functional class was analyzed
between groups using Kendall tau-b test. A 2-way
repeated-measures analysis of variance was used
for others to compare the effect of the intervention
between the 2 groups. For non-normally distributed
variables that failed normality testing with log
transformation, the changes between groups were
compared by an unpaired Student t test (2-tailed) or
Mann-Whitney U test as appropriate. Correlations
were performed with a bivariate Pearson r test. A p
value of 0.05 was considered to indicate statistical
signiﬁcance. The p values were not corrected for
multiple comparisons. Statistical analyses were per-
formed using IBM SPSS version 20 (IBM, Portsmouth,
United Kingdom).
SAMPLE SIZE. The primary endpoint was the change
in the PCr/ATP ratio after 4 weeks of treatment. Pilot
work from our group using the same 31P MRS tech-
nique with perhexiline revealed an improvement of
0.4 in the PCr/ATP ratio in the treatment group by
comparing means. The response was normally
distributed with an SD of 0.5. Using these data, 26
TABLE 1 Clinical Characteristics of the Patient Groups
Perhexiline
Group
Placebo
Group p Value
Age, yrs 62 " 1.8 60 " 2.43 0.49
Male 22 (88) 16 (64) 0.10
Body mass index, kg/m2 27 " 1.1 29 " 0.9 0.23
Body surface area, m2 1.9 " 0.04 1.9 " 0.04 0.88
Heart rate, beats/min 70 " 2.92 69 " 3.10 0.92
Systolic blood pressure, mm Hg 120 [35] 120 [34] 0.59
Diastolic blood pressure, mm Hg 60 [20] 60 [10] 0.72
Diabetes 4 2 0.38
Loop diuretics 16 20 0.21
ACE-I/ARBs 25 25 —
Beta-blockers 21 19 0.48
Calcium channel blockers 0 1 0.31
Spironolactone 14 13 0.78
Digoxin 7 4 0.31
Statins 13 9 0.24
Serum perhexiline level, mg/l
Week 1 0.17 " 0.04 0 —
Week 4 0.33 " 0.06 0 —
PCr/gATP ratio 1.16 " 0.08 1.38 " 0.07 0.04
NYHA functional class (class) 11 (II), 9 (III), 5 (IV) 14 (II), 10 (III), 1 (IV) 0.21
MLWHFQ score 25 [34] 36 [48] 0.79
LVEF, % 27 " 1.44 30 " 1.34 0.21
NT-proBNP level, pg/ml 620 [2,342] 241 [508] 0.02
Values are mean " SD, n (%), or median [interquartile range].
ACE-I/ARBs ¼ angiotensin-converting enzyme inhibitors/angiotensin receptor blockers;
ATP ¼ adenosine triphosphate; LVEF ¼ left ventricular ejection fraction; MLWHFQ ¼ Minnesota
Living With Heart Failure Questionnaire; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide;
NYHA ¼ New York Heart Association; PCr ¼ phosphocreatine.
FIGURE 2 Monitoring of Perhexiline Levels
Perhexiline levels were measured in all patients at the end of the ﬁrst week and again at
the conclusion of the intervention period. The dose of perhexiline was adjusted according
to the level in the ﬁrst week.
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subjects in each arm provided at least 80% power for
detecting a change of 0.4 in the PCr/ATP ratio.
RESULTS
STUDY POPULATION. Fifty patients were random-
ized, of whom 47 were included in the analysis
(Figure 1). One patient from the perhexiline group was
lost to follow-up due to a hospital admission with
intercurrent pneumonia at the time of follow-up. One
patient in the placebo group withdrew from the study
after randomization but before starting an interven-
tion. Another patient in the placebo group withdrew
due to adverse effects (headaches and lethargy). The
baseline clinical characteristics of the 2 groups are
shown in Table 1. The groups were matched for age,
sex, NYHA functional class, MLWHFQ scores, and
conventional medical therapy. The PCr/ATP ratio was
lower at baseline in the perhexiline group (1.16 " 0.08
vs. 1.38 " 0.07; p ¼ 0.036) and the NT-proBNP level
was higher (620 [2,342] pg/ml vs. 241 [508] pg/ml).
The mean serum perhexiline level at the end of
study in the perhexiline arm was 0.33 " 0.3 mg/l, with
2 patients (8.3%) falling below the lower threshold of
the therapeutic range (0.15 mg/ml) (Figure 2). There
were no signiﬁcant differences in venous metabolites
and insulin levels between the perhexiline and pla-
cebo groups.
MYOCARDIAL ENERGETICS. At baseline, the PCr/ATP
ratio correlated negatively with the MLWHFQ score
(r ¼ $0.361, p < 0.05). There was a signiﬁcant differ-
ence in mean PCr/ATP ratio between patients in
lower and higher NYHA functional classes (NYHA
functional class II mean PCr/ATP ratio: 1.47 " 0.05;
NYHA functional class III and IV mean PCr/ATP ratio:
1.06 " 0.07; p ¼ 0.0005) (Figure 3). There was no
signiﬁcant correlation between the PCr/ATP ratio
and LVEF (r ¼ 0.1, p ¼ 0.52) or NT-proBNP (r ¼ 0.01,
p ¼ 0.99) levels.
At follow-up, the myocardial PCr/ATP ratio
increased by 30% versus baseline in the perhexiline
group (1.16 " 0.39 to 1.51 " 0.51; p < 0.001) but did not
change in the placebo group (1.36 " 0.31 to 1.34 " 0.31;
p ¼ 0.37) (p < 0.001; 2-way repeated-measures anal-
ysis of variance) (Table 2, Figure 4). The 31P MRS
spectra of a patient before and after the intervention
TABLE 2 Effect of Perhexiline and Placebo
Parameter
Perhexiline Group Placebo Group
p Value
Before
Treatment
After
Treatment
Before
Treatment
After
Treatment
PCr/gATP ratio 1.16 " 0.39 1.51 " 0.51 1.36 " 0.31 1.34 " 0.31 <0.001
NHYA functional class,
(class)
11 (II), 9 (III),
5 (IV)
2 (I), 16 (II),
3 (III), 3 (IV)
14 (II), 10 (III),
1 (IV)
15 (II), 8 (III) 0.031
MLWHFQ score 25 [34] 20 [37] 36 [48] 27 [50] 0.20
NT-proBNP level, pg/ml 620 [2,342] 528 [1,670] 241 [508] 307 [455] 0.93
Values are mean " SD or mean [interquartile range].
Abbreviations as in Table 1.
FIGURE 3 Relationship Between PCr/ATP Ratio and NYHA Functional Class
The cardiac 31P MRS PCr/ATP ratio was markedly lower in those patients with higher NYHA
functional class. ATP ¼ adenosine triphosphate; NYHA ¼ New York Heart Association;
PCr ¼ phosphocreatine; other abbreviation as in Figure 1.
FIGURE 4 Change in PCr/ATP Ratio Between Baseline and
Follow-Up
The PCr/ATP ratio was not well matched between groups at
baseline. There was a signiﬁcant increase in the PCr/ATP ratio
with perhexiline therapy from 1.16 " 0.39 to 1.51 " 0.51
compared with placebo (p< 0.001). Abbreviations as in Figure 3.
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are shown in Figure 5. The mean CRLBs for PCr and
ATP for the entire group were 10.7% and 12.7%,
respectively, indicating a satisfactory signal-to-noise
ratio (20). Three patients were excluded from the
initial analysis because of a poor signal-to-noise ratio
(CRLBs >20%).
SYMPTOMS. At follow-up, there was an improvement
in NHYA functional class in the perhexiline group
compared with the placebo group (p ¼ 0.036). Thir-
teen patients in the perhexiline group improved by
1 NHYA functional class (52%) compared with 5
patients (20%) in the placebo group (p ¼ 0.02). No
patient changed by more than 1 NYHA functional
class (Table 2).
ECHOCARDIOGRAPHY. There was no change in the
secondary endpoint of LVEF in the perhexiline group
(27 " 1.44% to 26 " 1.77%) compared with the placebo
group (30 " 1.34% to 29 " 1.96%) (p ¼ 0.68). More
sensitive measures of left ventricular function were
sought by analyzing results derived from longitudinal
strain measurements. Of the 47 patients who under-
went echocardiography before and after the inter-
vention, only 27 had adequate images for longitudinal
strain and strain rate analysis (perhexiline: 12; pla-
cebo: 15) from speckle tracking echocardiography.
This showed no change in peak global systolic strain
or strain rate between the groups. Rotational strain
analysis was available in 24 patients (perhexiline: 13;
placebo: 11) and showed no change in either absolute
twist or twist rate (data not shown).
VENOUS BLOOD METABOLITES AND NT-proBNP
LEVELS. After the intervention, there were no dif-
ferences in venous metabolites, NT-pro-BNP levels,
or insulin levels between the groups (Tables 2 and 3).
CROSS-HEART METABOLISM. Cross-heart sampling
from the invasive studies did not show a group dif-
ference in metabolite extraction (Table 4). The respi-
ratory quotient was similar between the groups
(perhexiline: 0.86 " 0.06; placebo: 0.90 " 0.16;
p ¼ 0.63). In the cross-heart sampling group, per-
hexiline therapy was associated with an increase in
the PCr/ATP ratio of 0.51 " 0.18, whereas placebo was
associated with a reduction in the PCr/ATP ratio of 0.1
" 0.16 (p < 0.005 for between-group difference).
ADVERSE EFFECTS. Adverse effects included nausea
(n ¼ 3), dizziness (n ¼ 1), and diarrhea (n ¼ 1) in the
perhexiline group and headaches (n ¼ 1), lethargy
(n ¼ 1), and metallic taste in the mouth (n ¼ 1) in the
placebo group. There were no instances of hepato-
toxicity and no deaths or major adverse events during
the study period. In the perhexiline group, 2 patients
had subtherapeutic levels, and 2 patients had levels
above the therapeutic level at the end of the study
period (Figure 2).
DISCUSSION
This is the ﬁrst study to show that short-term per-
hexiline therapy leads to an improvement in cardiac
energetics without a shift in substrate utilization.
Importantly, this was associated with an improve-
ment in NYHA functional class.
We have previously shown that perhexiline leads
to an improvement in the PCr/ATP ratio in patients
with hypertrophic cardiomyopathy after 5 months of
therapy (6). In the present study, the effects of per-
hexiline on the PCr/ATP ratio were observed by
1 month of therapy with a regimen that typically takes
FIGURE 5 An Example of 31P MRS Before and After Treatment With Perhexiline
a, b, and g ¼ the 3 phosphorus nuclei of ATP; C ¼ center of the coil; 2,3-DPG ¼ 2,3-
diphosphoglycerate; PDE ¼ phosphodiesterase; VOI ¼ voxel of interest; other abbrevia-
tions as in Figures 1 and 3.
TABLE 3 Effect of Perhexiline on Venous Metabolites and Insulin
Parameter
Perhexiline Group Placebo Group
p Value
Before
Treatment
After
Treatment
Before
Treatment
After
Treatment
Glucose, mmol/l 5.81 " 0.79 5.85 " 0.79 6.42 " 1.11 6.43 " 0.37 0.75
Glycerol, mmol/l 75.02 " 63.2 87.36 " 68.71 74.98 " 40.00 68.50 " 30.34 0.55
Lactate, mmol/l 1.34 " 0.49 1.42 " 0.69 1.35 " 0.49 1.49 " 0.85 0.99
NEFA, mmol/l 0.52 " 0.36 0.54 " 0.29 0.56 " 0.35 0.39 " 0.11 0.20
Triglycerides, mmol/l 1.25 " 0.37 1.23 " 0.21 1.31 " 0.43 1.30 " 0.59 0.68
Pyruvate, nmol/ml 17.95 " 6.76 19.50 " 8.32 19.23 " 9.96 16.86 " 9.83 0.35
Insulin, mU/ml 9.49 " 4.70 10.02 " 1.96 17.27 " 14.31 14.03 " 6.74 0.11
Values are mean " SD.
NEFA ¼ nonesteriﬁed fatty acids.
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approximately 2 weeks to achieve therapeutic levels.
This marked change in energetics is thus an early
phenomenon, occurring before any demonstrable ef-
fect on resting cardiac performance, which is consis-
tent with this being a direct effect of the drug on
cardiac energetics rather than an improvement due to
a longer-term improvement in the HF syndrome with
consequent molecular reverse remodeling.
An important ﬁnding of this study is that the
improvement in cardiac energetics with perhexiline
occurs without any evidence of altered whole blood
substrate levels. Furthermore, we did not see any
difference in cross-heart substrate gradients or in
cross-heart RER between the perhexiline and placebo
groups. This is important because the latter provides
a measure of relative substrate utilization (carbohy-
drate vs. fatty acids) derived from both uptake from
plasma and from cardiac stores. A lower fatty acid
oxidation and a greater reliance on carbohydrate
oxidation would be expected to have manifested as a
higher cross-heart RER. There was no signiﬁcant dif-
ference between the groups, but the mean RER was
actually lower in the perhexiline group. These ﬁnd-
ings are consistent with those of a study in the
working rat heart model in which very short-term
treatment with perhexiline was associated with a
substantial improvement in cardiac mechanical efﬁ-
ciency at a stage before the demonstration of reduced
palmitate uptake (21). However, this might have been
attributable to an early reduction in use of fatty acids
derived from myocyte triglyceride stores before a
reduction in myocardial fatty acid uptake.
The mechanism(s) responsible for our observations
of improved energetics with perhexiline are unclear.
Although longer duration and/or higher plasma con-
centrations may well alter substrate use, our obser-
vations suggest additional or alternate mechanisms
for improved energetics. Treatment with perhexiline
has been reported to inhibit NADH/NADPH, thereby
reducing reactive oxygen species generation (22),
and to inhibit mTORC1 and thereby potentially in-
crease autophagy, including mitophagy (23). It may
potentially have other pleotropic actions. A recent
study reported a direct effect of trimetazidine on the
mitochondrial electron transport chain in an experi-
mental HF model (24), but this has not been assessed
with perhexiline.
The lack of improvement in LVEF with perhexiline
therapy conﬂicts with a prior study of perhexiline and
with several studies of the metabolic modulator tri-
metazidine. A recent meta-analysis of trimetazidine
in patients with HF showed an improvement in LVEF
in patients with both ischemic and nonischemic HF
(25). Lee et al. (5) showed an unprecedented 10%
improvement in LVEF with perhexiline. The likely
explanation for this is related to the purpose of this
study, which was intended to ensure only short-term
therapeutic plasma perhexiline levels to assess
whether cardiac energetic improvement was a very
early ﬁnding. We postulate that if treatment with
perhexiline were continued in these patients, we
would likely have seen a corresponding improvement
in LVEF and NT-proBNP levels.
Despite the lack of change in LVEF, there was an
improvement in NYHA functional class in the
perhexiline-treated patients. This has been shown
previously with both perhexiline (5) and trimetazi-
dine (26). In a randomized, double-blind study, Lee
et al. (5) showed that perhexiline therapy for 2
months led to a 21% reduction in NHYA functional
class. This is comparable to the 17% reduction
observed in the present study. Fragasso et al. (26) also
showed a 19% reduction in NHYA functional class
with trimetazidine. Such improvements in functional
class have previously been attributed to both im-
provements in skeletal muscle function due to the
effects of perhexiline on skeletal muscle or to im-
provements in cardiac output. Lee et al. (5) also per-
formed 31P MRS on skeletal muscle and showed
improvement in PCr recovery time after exercise. The
present study suggests that these changes occur
before a demonstrable improvement in resting echo-
cardiographic measures of LVEF and that they are
either due to skeletal muscle effects and/or that
improved cardiac performance during exercise pre-
cedes improvements in resting parameters.
STUDY LIMITATIONS. The number of patients was
small and was not well matched at baseline, with
those randomized to perhexiline having more severe
HF, which could have had a signiﬁcant impact on the
baseline substrate utilization. Furthermore, for
ethical reasons, it was not possible to submit patients
to invasive studies before and after the intervention,
which clearly would have been more robust. Never-
theless, given the substantial improvement in cardiac
TABLE 4 Cross-Heart Differences in Metabolites
Parameter
Perhexiline Group Placebo Group
p ValueArterial Venous Arterial Venous
Glucose, mmol/l 5.20 " 0.20 5.04 " 0.31 5.12 " 0.33 4.98 " 0.13 0.24
Lactate, mmol/l 0.79 " 0.11 0.63 " 0.11 0.52 " 0.08 0.47 " 0.10 0.20
NEFA, mmol/l 1.07 " 0.52 0.82 " 0.51 0.77 " 0.14 0.57 " 0.16 0.12
Pyruvate, nmol/ml 4.52 " 3.14 3.82 " 4.87 6.42 " 1.19 5.78 " 1.58 0.48
Values are mean " SD.
Abbreviation as in Table 3.
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energetics observed in these patients, we would have
expected to see a difference in the on-treatment cross-
heart substrate uptake and/or respiratory quotient if
perhexiline were working through such a mechanism.
In our hands, the coefﬁcient of variation for the
measurement of RER was 9%. Although this was a
secondary endpoint and our power calculations were
on the basis of the primary endpoint, our sample size
would have 80% power to detect a difference in RER
between the 2 groups of 0.15. Accordingly, although
we cannot exclude the possibility of a type II error
resulting in failure to detect a modest difference in
RER between the 2 groups, it seems unlikely that a
shift in substrate utilization of sufﬁcient magnitude
to entirely explain the substantial effect of perhexi-
line on the cardiac PCr/ATP ratio would have been
missed.
CONCLUSIONS
We have shown that short-term perhexiline therapy
leads to improved cardiac energetics and NYHA
functional class without altering substrate utilization
or left ventricular function. This study supports the
hypothesis of energy deﬁciency in HF and further
consideration of metabolic therapies in the manage-
ment of HF. Alternative mechanisms of action for
perhexiline to explain these ﬁndings need to be
explored.
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